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1. Introduction
Bleeding from esophagogastricvarices is a catastrophic complication of chronic liver disease.
There are various treatments for esophagogastricvarices, such as endoscopic treatment, in‐
terventional radioligy, and surgical procedure [1-3]. Recently, "General Rules for Recording
Endoscopic Findings of EsophagogastricVarices [4]" were establised and endoscopic treat‐
ment further improved survival rates [5].
Many years ago, operation was the only treatment available. A number of surgical proce‐
dures have been developed to manage esophagogastricvarices [6]. Broadly, these can be
classified as shunting and nonshunting procedures.
We showed the surgical procedures for the treatment of esophagogastricvarices.
2. Operation technique
2.1. Shunting procedures
There are various shunting procedures for the treatment of esophagogastricvarices [7-25].
There are two types of shunting procedures, nonselective shunt and selective shunt. Nonse‐
lective shunts, such as portacaval or mesocaval shunts, reduce portal venous pressure and
improve esophagogastricvarices. While nonselective shunt is associated with a high risk of
hepatic encephalopathy secondary to the hyperammonemia that is caused by impaired pro‐
tein metabolism in the liver [26-28].
Selective shunts, such as distal splenorenal shunt (DSRS) or left gastric venous caval shunt
(Inokuchi shunt), maintain portal pressure and selectively reduce esophagogastricvariceal
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pressure. Shunt surgery is the best procedure in terms of preventing recurrent bleeding
[20-22], but carries a high risk of postoperative encephalopathy, especially after nonselective
shunt [26-28]. Even in selective shunt, loss of shunt selectivity occurs occasionally, leading to
postoperative encephalopathy [8, 14].
2.1.1. Nonselective shunt
2.1.1.1. Portacaval and mesocaval shunt
The mesocaval shunt was initially used to control bleeding from esophageal varices in chil‐
dren with congenital abnormalities of the hepatobiliary system. The procedure consisted of
transposition of the divided inferior vena cava and the divided superior mesenteric vein,
hence its name, mesocaval shunt. This operation was modified, and some reports have de‐
scribed a portacaval or mesocaval interposition shunt with a graft (H-graft mesocaval shunt)
[9, 10, 29-33]. Millikan et al. [26] have reported that the incidence of hyperammonemia after
nonselective shunt procedures was as high as 75%.
2.1.2. Selective shunt
2.1.2.1. Left gastric venous caval shunt (Inokuchi shunt)
To assure postoperative portal perfusion and to prevent Eck’s syndrome, in 1967 Inokuchi
designed a selective shunt, called the left gastric venous caval shunt [7, 19, 23-25].
After dilatation, and engorgement of the left gastric vein is confirmed by splenoportogra‐
phy, the gastrohepatic ligament is opened and the left gastric vein is identified, and dis‐
sected  2  cm  towards  its  junction  with  the  portal  system  or  splenic  vein.  The  vein
dissection must be done carefully to avoid hemorrhage, since the wall of the left gastric
vein is weak due to increased portal vein pressure. The anastomosis is then performed be‐
tween the distal end of the transected left gastric vein and the inferior vena cava. The au‐
tograft, the great saphenous vein, is anastomosed to the inferior vena cava in an end-to-
side  fashion,  and  opposite  end  is  pulled  through  the  suprapancreatic  space.  After  the
anastomosis  is  completed,  a  splenectomysi  done.  If  splenectomy is  not  indicated,  short
gastric  vein ligation is  necessary in order  to  decrease the collateral  circulation from the
greater curvature of the stomach. The selection of a caval anastomosis procedure depends
upon anatomical individuality or operative difficulty or both. The left gastric venous-caval
shunt  can be modified in  three  ways,  left  gastric-spermatic  (ovarian)  shunt,  left  gastric-
adrenal shunt, or left gastric-renal shunt.
Postoperative mean portal pressure was 335 mm of water, and although it is decreased whe
compared to 363 mm water at laparotomy, this may be the result of solenectomy. On the




Original DSRS: The DSRS is a selective shunt that was developed by Warren (original DSRS)
in 1967 [12] to preserve portal blood flow through the liver while lowering variceal pressure.
The hope was that both bleeding and hyperammonemia would be prevented. DSRS effec‐
tively prevents rebleeding, but still carries a risk of hyperammonemia [14].
The procedure for DSRS consists of anastomosis of the distal end of the splenic vein to the
left renal vein, and devascularization of left gastric artery and vein. The specific objectives of
DSRS as stated in the original publication [12] were : 1) selective reduction of pressure and
volume of flow through gastroesophageal veins; 2) maintaining portal venous perfusion of
the liver; and 3) maintaining continual venous hypertension in the intestinal bed. These
three objectives formed a basis for much subsequent work.
Henderson et al. [34]compared hemodynamics between alcoholic and nonalcoholic cirrhotic
patients after DSRS. Portal perfusion and liver blood flow are maintained, both quantitative‐
ly and qualitatively, in nonalcoholic patients with cirrhosis, resulting in better hepatocyte
function and improved survival.
Stenosis of a DSRS shunt may lead to inadequate variceal decompression, accompanied by a
risk of rebleeding. Henderson et al. [35]reported that the patients with stenosis of a DSRS
were successfully managed by balloon dilation. All of the shunts were patent, but showed a
mean pressure gradient of 15 millimeters of mercury, which was reduced to a mean of 7 mil‐
limeters of mercury by dilation. Although, repeat angiography should be performed in pa‐
tients with rebleeding or reappearance of varices after DSRS to determine the cause.
DSRS + splenopancreatic disconnection (SPD): Belghiti et al. [8] reported loss of shunt selec‐
tivity during long-term follow-up in patients who underwent original DSRS, confirmed via
the pancreatic vein. Warren et al. [36] subsequently improved the DSRS procedure by add‐
ing SPD, i.e., skeletonization of the splenic vein from the pancreas to its bifurcation at the
splenic hilum. The operation technique is as follows: The pancreas is approached through
the lesser sac, with the additional takedown of the splenic flexure to improve access to the
retropancreatic plane. The whole pancreas is mobilized along its inferior border from the su‐
perior mesenteric vein to the splenic hilus. The pancreatic perforating veins are ligated as
they enter the splenic vein. It is imperative to sufficiently dissect the splenic vein from the
pancreas and to carefully manipulate the junction between the splenic and superior mesen‐
teric vein to ensure that skeletonization proceeds to the renal vein without kinking. The key
to the entire procedure lies in accurate identification and ligation of the pancreatic perforat‐
ing veins as they enter the splenic vein. The anastomosis should also be performed without
tension or kinking of the splenic vein. Typically, the anastomosis lies just in front of the li‐
gated adrenal vein on the left renal vein with continuous suture.
Moon et al. [37] examined the outcomes of DSRS+SPD in children to evaluate the usefulness
of this operation. The platelet count and white cell count increased significantly after DSRS
+SPD. Spleen size decreased significantly. No patient underwent subsequent transplantation
or endoscopic treatment for esophagogastricvarices after DSRS+SPD.
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DSRS + SPD + gastric transection (GT): Loss of shunt selectivity was still observed via collat‐
eral pathways through the stomach [20]. We therefore modified DSRS by additionally per‐
forming SPD and GT to prevent loss of shunt selectivity. GT involved transection and
anastomosis of the upper stomach with an autosuture instrument. The short gastric arteries
and veins were spared. Katoh et al. [38] performed transection and re-suture of the seromus‐
cular layer of the upper stomach to prevent loss of selectivity after DSRS + SPD. They called
this procedure “superselective DSRS.” We performed transection of all layers, whereas Ka‐
toh et al. transected only the seromuscular layer of the upper stomach.
We compared long-term results for three types of DSRS for the treatment of esophageal vari‐
ces.  Additional treatment for recurrent varices was required in the original DSRS group
(9.1%), DSRS with SPD group (18.2%), and DSRS with SPD plus GT group (4.3%). All of the
patients with recurrent varices had shunt stenosis within the first year after DSRS. The preva‐
lence of hyperammonemia in the DSRS with SPD plus GT group was significantly lower than
that in the original DSRS group and the DSRS with SPD group (P<0.01). There were no signifi‐
cant differences in survival among the three groups. DSRS with SPD plus GT may reduce the
incidence of postoperative hyperammonemia [14]. Kanaya et al. [39] have reported that the
incidence of hyperammonemia after DSRS with SPD plus gastric disconnection (transection
of only the seromuscular layer of the upper stomach) was 3.2%. We found that the prevalence
of hyperammonemia after DSRS with SPD plus GT was 0% at 1 year, 9.1% at 5 years, and 9.1%
at 10 years [14]. The loss of shunt selectivity promotes hyperammonemia and decreases por‐
tal blood flow. High serum ammonia concentrations result in encephalopathy. We previously
reported that obliteration of portosystemic shunts followed by partial splenic embolization is
beneficial in patients with portosystemic encephalopathy. Portal venous pressures were simi‐
lar before and after treatment in patients who underwent embolization of portosystemic
shunts followed by partial splenic embolization [40, 41]. In patients who had portosystemic
encephalopathy after DSRS, however, elevated portal venous pressures after embolization of
portosystemic shunts can notreduced by partial splenic embolization. Fisher et al. [42] have
reported normalization of hyperammonemia after administration of a solution enriched with
branched chain amino acids. All patients with hyperammonemia in our study should re‐
ceived branched chain amino acids [14]. However, patients with hyperammonemia require
long-term nutritional support, negatively affecting their quality of life. Liver dysfunction was
controlled with good nutritional support. We found no significant differences in cumulative
survival among the original DSRS group, DSRS with SPD group, and DSRS with SPD plus GT
group [14]. Kanaya et al. [39] have reported better 5- and 7-year survival rates after DSRS with
SPD plus gastric disconnection than after standard DSRS.
Santambrogio et al. [43] compared endoscopic injection sclerotherapy (EIS) with DSRS for
the prevention of recurrent variceal bleeding in cirrhotic patients who underwent long-term
follow-up. They concluded that DSRS with a correct portal-azygos disconnection more effec‐
tively prevents varicealrebleeding than EIS in a subgroup of patients with good liver func‐
tion. However, this positive effect did not influence long-term survival because other factors
(e.g., hepatocellular carcinoma) were more important determinants of the outcomes of the
cirrhotic patients with portal hypertension.
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Rikkers et al. (13)performed a prospective, randomized trial to evaluate the effectiveness of
DSRS for the treatment of cirrhotic patients who previously had bleeding from esophageal
varices. A total of 55 patients were randomly assined to receive a DSRS (26 patients) or a
nonselective shunt (29 patients). Three operative deaths occurred in each group. Early post‐
operative angiography revealed preservation of hepatic portal perfusion in 14 of 16 selective
patients (88%), but in only 1 of 20 nonselective patients (p<0.001). Quantitative measures of
hepatic function (maximal rate of urea synthesis and Child’s score) were similar to preoper‐
ative values in the selective shunt, but had significantly decreased in the nonselective shunt
on the first postoperative evaluation. Encephalopathy has not developed in any patient with
continued portal perfusion, as compared with 45% of patients without portal flow (p<0.05).
No significant differences the between selective and nonselective shunt have been detected
with respect to total cumulative mortality (10 selective, 38%; 8 nonselective, 28%), shunt oc‐
clusion (2 selective, 10%; 5 nonselective, 18%), or recurrent variceal hemorrhage (1 selective,
4%; 2 nonselective, 8%). Overall, postoperative encephalopathy has developed in significant‐
ly fewer selective patients (3 selective, 12%; 15 nonselective, 52%; p<0.001). Therefore, they
conclude that the DSRS, especially when its objective of maintaining hepatic portal perfu‐
sion is achieved, results in significantly less morbidity than nonselective shunt.
Warren et al. (44) reported the metabolic basis of portosystemic encephalopathy and com‐
pared the effects of selective vs. nonselective shunts. Metabolic studies were done in the Clini‐
cal  Research  Unit  during  a  14-day  stay  under  carefully  controlled  dietary  conditions.
Maximal rate of urea systhesis did not change in patients with DSRS, but decreased signifi‐
cantly in those with nonselective shunt. Likewise, ammonium chloride tolerance, defined as
the smallest dose required to produce a 40-µg/dL rise in the plasma ammonia concentration,
was unchanged in the DSRS group, but significantly worsened in the nonselective shunt
group.
Galambos et al. [45]compared nonselective shunt with selective shunt for the treatment of
bleeding esophageal varices in a randomized controlled trial. A total of 48 patients were ran‐
domly assigned to receive a nonselective shunt (24 patients) or a selective shunt (24 pa‐
tients). Mortality rates, the frequencies of shunt occlusion, and the frequencies of recurrent
gastrointestinal bleeding were similar. Encephalopathy developed more often after a nonse‐
lective shunt than after a selective shunt. Nonselective shunts consistently diverted the hep‐
atopetal mesenteric-portal flow from the liver. Deterioration of hepatic function was greater
after nonselective than selective shunt.
2.2. Nonshunting procedures
Historically, nonshunting procedures were developed in an attempt to decrease the high rates
of encephalopathy associated with portosystemic anastomoses. An alternative to total shunt
was developed by Sugiura and Futagawa in 1973 [46]. Esophageal transection (ET) disrupts
the blood supply to esophagogastricvarices. ET solves the problem of hepatic encephalop‐
athy; unfortunately, however, varices can recur because portal pressure remains high.
Various nonshunting procedures, such as the Hassab operation, ET, splenectomy, or termi‐
nal esophago-proximal gastrectomy, have been developed to treat esophagogastricvarices
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[46-49]. All nonshunting procedures performesplenectomy. Portal vein thrombosis is not a
rare complication of splenectomy and can be fatal in patients with hypersplenism. Kawana‐
ka et al. reported that low antithrombin 3 activity and futher decreases in this activity are
associated with portal vein thrombosis after splenectomy in cirrhotic patients, and that treat‐
ment with antithrombin 3 concentrates is likely to prevent the development of portal vein
thrombosis in thease patients [50].
2.2.1. Splenectomy
Splenectomy was one of the earliest nonshunting procedures. It was found to be generally
ineffective for preventing recurrent variceal bleeding [51]. Despite elimination of the splenic
component of the portal circulation, portal hypertension is maintained after simple splenec‐
tomy, and the risk of continued bleeding via the splenic venous branches is high.
Recently, laparosopicsplenectomy is wadely accepted as a standard treatment for hemato‐
logic disorders such as idiopathic thrombocytopenic purpura. Laparoscopic splenectomy is
improved safty in liver cirrhosis patients with portal hypertension [52].
2.2.2. Hassab operation
In 1967, Hassab [47] reported a successful technique for gastroesophageal decongestion and
splenectomy, developed in Egypt. Most of his patients had schistosomiasis. The operation
entailed removal of the spleen as well as devascularization of the cardiac portion of the
stomach and abdominal portion of the esophagus, including the supraphrenic veins. By li‐
gating the left gastric artery and splenic artery, portal blood flow was also decreased, there‐
by decompressing the portal system. Recently, the Hassab operation has been employed in
patients with varices limited to the stomach.
2.2.3. Terminal esophago-proximal gastrectomy
Terminal esophago-proximal gastrectomy involves proximal gastric transection and autosuture
proximal gastrectomy in association with extensive devascularization and splenectomy [49].
2.2.4. ET
Among non-shunting procedures for the treatment of esophagogastricvarices, ET has been
the most popular operation. ET in Japan was first performed in 1967 [53], using a modifica‐
tion of Walker’s procedure for transthoracic ET [54]. The procedure was then refined by Su‐
giura and Futagawa in 1973 [46]. ET consists of paraesophagealdevascularization,
esophageal transection and reanastomosis, splenectomy, and pyloroplasty. First, splenecto‐
my with devascularization of the greater curvature was performed. Devascularization of the
lesser curvature was done from the angle to the esophagogastric junction, and the left gas‐
tric artery was ligated and divided. The esophagus and cardia were devascularized from the
lesser to the greater curvature. Then, the vagal nerve and paraesophageal vessels were ligat‐
ed and divided. The esophagus was completely transected above the esophagogastric junc‐
tion, and the mucosa was anastomosed with interrupted sutures, performed recently with
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an autosuture instrument. ET was done using three different approaches, transthoracic,
thoracoabdominal, and transabdominal. Devascularization of the esophagus and the stom‐
ach is most extensive and complete in the thoracoabdominal approach; however, this is the
most drastic procedure.
Sugiura et al. [55] reported on 636 patients with portal hypertension in whom ETs with par‐
aesophagogastricdevascularization were performed to manage esophageal varices. The op‐
erative mortality rates were as follows: emergency cases 13.7%, elective cases 3.2%,
prophylactic cases 4.3%, and overall 5.2%. There were no deaths among the 233 patients in
Child’s class A; the 232 patients in class B had a 2% mortality rate, and the 171 patients in
class C had a 17% mortality rate. The 10-year actuarial survival rates in patients with cirrho‐
sis were 55% in emergency cases, 72% in prophylactic cases, and 72% in elective cases. In
patients without cirrhosis, the corresponding survival rates were 90%, 96%, and 95%, re‐
spectively. The recurrence rate of variceal bleeding or varices was less than 5%. They con‐
cluded that the Sugiura procedure is safe and effective for controlling esophageal varices
and prolongs the long-term survival of patients with portal hypertension.
In our study, however, the recurrence rate of varices after ET was high [21]. We examined he‐
modynamic changes associated with recurrent esophageal varices after ET and evaluated the
effectiveness of EIS for their treatment. Nineteen patients with recurrent esophageal varices af‐
ter ET were treated by EIS. Endoscopic varicealography during injection sclerotherapy (EVIS),
following oral blockage of flow by a balloon, identified three patterns: type 1 (common type),
continuous filling by the feeder vessel of the varix; type 2 (retrograde disappearing type), con‐
firmed hepatofugal flow; and type 3 (immediate washout type), immediate washout of con‐
trast medium. Angiography showed that the hepatofugal feeder vessel was the right gastric
vein in all cases. Recurrent esophageal varices were classified as type 1 in 14 patients (73.7%),
type 2 in 4 (21.1%), and type 3 in 1 (5.3%). Fewer treatment sessions were required in type 1 than
in type 2 varices (p<0.005). Recurrent varices were completely eradicated in all patients except
the patient with type 3 disease. Cumulative re-recurrence rates at 5 and 10 years were higher in
type 1 than in type 2 varices without significance (28.6% and 71.4% vs. 25.0% and 25.0%, respec‐
tively). Cumulative survival rates after EIS at 5 and 10 years also were similar for type 1 and
type 2 varices (77.1% and 66.1% vs. 66.7% and 66.7%). EIS was thus effective for the manage‐
ment of recurrent esophageal varices after ET, excluding type 3 disease [56].
Cleva et al. [57] compared the systemic hemodynamic effects of DSRS with those of esopha‐
gogastricdevascularization and splenectomy in patients treated for schistosomal portal hy‐
pertension. The hyperdynamic circulatory state observed in Manson’s schistosomiasis was
corrected by esophagogastricdevascularization and splenectomy, but persisted in patients
who underwent DSRS. Similarly, the elevated mean pulmonary artery pressure resolved af‐
ter esophagogastricdevascularization and splenectomy, but persisted after DSRS. They con‐
cluded that esophagogastricdevascularization and splenectomy seems to be the most
physiologic operation for patients with schistosomal portal hypertension.
We compared the long-term results of DSRS and ET in cirrhotic patients with complete vari‐
ceal eradication who were followed up for at least 3 years. There was no recurrent varix in
the DSRS group. The cumulative recurrence rates of varices in the ET group were 31.6% and
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52.5% at 5 and 10 years, respectively. The cumulative rates of hyperammonemia at 5 and 10
years were significantly higher in the DSRS group (30.4%, 30.4%) than in the ET group (0%,
5.6%) (p=0.009). The cumulative survival rates in the DSRS group vs. the ET group were
90.9% vs. 94.7% at 5 years and 85.2% vs. 81.7% at 10 years (NS). These results suggest that
DSRS is more effective than ET in preventing recurrence of esophageal varices, but is associ‐
ated with a higher incidence of hyperammonemia [21]. In that study, no patient who under‐
went DSRS with complete eradication had recurrent varices. When collateral pathways to
the esophagus develop after DSRS, flow is via the short gastric veins, the splenic vein, and
the left renal vein. After ET, collateral pathways to the esophagus develop across the trans‐
ection site and generate new varices. Most of the recurrent varices in the ET group were
supplied by the right gastric vein across the transection site [56]. However, collateral flow in
the DSRS group decreased hepatic blood flow and led to the development of postoperative
hyperammonemia. Rikkers et al. [58] reported that patients with no hepatic portal perfusion
had the worst survival and greatest morbidity after DSRS.
Idiopathic portal hypertension (IPH) is a disease of unknown etiology characterized by spleno‐
megaly, anemia, and portal hypertension. This disorder develops in the absence of liver cirrho‐
sis, extrahepatic portal vein occlusion, schistosomiasis, or any other identifiable cause [59, 60].
We evaluated the results of shunting and nonshunting procedures for the treatment of esopha‐
gogastricvarices in patients with IPH. Esophagogastricvarices were completely eradicated in 3
(75.0%) patients in the shunting group and 4 (80.0%) in the nonshunting group. Additional en‐
doscopic treatment (one session) was performed in 2 patients with incompletely eradicated
varices. There was no recurrence in the shunting group. In the nonshunting group, esophago‐
gastricvarices recurred in all  4 patients with completely eradicated varices.  All  recurrent
esophageal varices were completely eradicated. Postoperative platelet counts (×104/µL) were
significantly lower in the shunting group (10.0±2.6) than in the nonshunting group (42.0±14.0)
(p=0.0029). The increase in the platelet count after operation was significantly lower in the
shunting group (1.7±0.2 times) than in the nonshunting group (5.8±2.9 times) (p=0.0267). No
patient received anticoagulants postoperatively. Portal venous thrombus did not develop in
the shunting group, but appeared in 4 patients (80.0%) in the nonshunting group. No patient
had loss of shunt selectivity or portal-systemic encephalopathy. One patient in the nonshunt‐
ing group died of cerebral hemorrhage; all others are alive. Shunting procedure, DSRS, was
suggested to be useful for the management of esophagogastricvarices in patients with IPH [61].
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